| Q34172349 | 'Designer drugs'. A problem in clinical toxicology |
| Q47777762 | (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA. |
| Q33540473 | 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. |
| Q22299243 | 3,4-Methylenedioxymethamphetamine's (MDMA's) Impact on Posttraumatic Stress Disorder |
| Q42099134 | A review of transpersonal theory and its application to the practice of psychotherapy |
| Q45071429 | A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. |
| Q37012610 | Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons |
| Q48824498 | Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy"). |
| Q35095703 | Altered states: the clinical effects of Ecstasy. |
| Q52803481 | Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder. |
| Q57176236 | Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine |
| Q33923930 | Developmental effects of 3,4-methylenedioxymethamphetamine: a review |
| Q41150965 | Dual serotoninergic projections to forebrain in the rat: Morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives |
| Q44418655 | Ecstasy: a review of scientific literature about MDMA |
| Q48463442 | Effects of Schedule I drug laws on neuroscience research and treatment innovation |
| Q34325119 | Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes |
| Q26859367 | Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans |
| Q37149027 | MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology |
| Q21558551 | MDMA for the treatment of mood disorder: all talk no substance? |
| Q48095503 | MDMA induces EPSP-Spike potentiation in rat ventral hippocampus in vitro via serotonin and noradrenaline release and coactivation of 5-HT4 and beta1 receptors |
| Q41278263 | MDMA produces stimulant-like conditioned locomotor activity |
| Q39823186 | Malignant hyperpyrexia in an MDMA ("Ecstasy") abuser |
| Q55043421 | Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): Neurodegeneration versus Neuromodulation. |
| Q34976260 | Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. |
| Q51482161 | Neurochemical binding profiles of novel indole and benzofuran MDMA analogues. |
| Q36548689 | Neurogenic bladder and chronic urinary retention associated with MDMA abuse |
| Q44865152 | Neurotoxicity of methamphetamine and methylenedioxymethamphetamine |
| Q37184290 | Oxytocin receptor gene variation predicts subjective responses to MDMA. |
| Q48221705 | Reckless behaviour related to the use of 3,4-methylenedioxymethamphetamine (ecstasy): apropos of a fatal accident during car-surfing |
| Q40483217 | Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). |
| Q44385002 | Serotonergic-dopaminergic mediation of MDMA's discriminative stimulus effects in a three-choice discrimination |
| Q30341737 | The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). |
| Q36734781 | The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review |
| Q34546304 | The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens |
| Q22252794 | Toxicity of amphetamines: an update |
| Q89716254 | Translating molecular and neuroendocrine findings in posttraumatic stress disorder and resilience to novel therapies |
| Q44638832 | ‘Ecstasy’-induced subarachnoid haemorrhage: an under-reported neurological complication? |